These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27845774)

  • 1. Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis.
    Suvitaival T; Mantere O; Kieseppä T; Mattila I; Pöhö P; Hyötyläinen T; Suvisaari J; Orešič M
    Transl Psychiatry; 2016 Nov; 6(11):e951. PubMed ID: 27845774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-generation antipsychotics and the metabolic syndrome.
    Masand PS; Mago R
    Curr Psychiatry Rep; 2005 Jun; 7(3):153-4. PubMed ID: 15935125
    [No Abstract]   [Full Text] [Related]  

  • 3. Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up.
    Attux C; Quintana MI; Chaves AC
    Braz J Psychiatry; 2007 Dec; 29(4):346-9. PubMed ID: 17992359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Circulating Lipids and Future Weight Gain in Individuals With an At-Risk Mental State and in First-Episode Psychosis.
    Lamichhane S; Dickens AM; Sen P; Laurikainen H; Borgan F; Suvisaari J; Hyötyläinen T; Howes O; Hietala J; Orešič M
    Schizophr Bull; 2021 Jan; 47(1):160-169. PubMed ID: 32609372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Psychotropic drugs and diabetes].
    Ress C; Tschoner A; Kaser S; Ebenbichler CF
    Wien Med Wochenschr; 2011 Nov; 161(21-22):531-42. PubMed ID: 21792529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
    Pérez-Iglesias R; Martínez-García O; Pardo-Garcia G; Amado JA; Garcia-Unzueta MT; Tabares-Seisdedos R; Crespo-Facorro B
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):41-51. PubMed ID: 24103107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.
    Correll CU; Robinson DG; Schooler NR; Brunette MF; Mueser KT; Rosenheck RA; Marcy P; Addington J; Estroff SE; Robinson J; Penn DL; Azrin S; Goldstein A; Severe J; Heinssen R; Kane JM
    JAMA Psychiatry; 2014 Dec; 71(12):1350-63. PubMed ID: 25321337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotic induced metabolic changes & treatment response: a prospective study.
    Sharma E; Venkatasubramanian G; Varambally S; Sivakumar PT; Subbakrishna DK; Gangadhar BN
    Asian J Psychiatr; 2014 Oct; 11():39-44. PubMed ID: 25453695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
    Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication: a review.
    Koponen H; Saari K; Savolainen M; Isohanni M
    Eur Arch Psychiatry Clin Neurosci; 2002 Dec; 252(6):294-8. PubMed ID: 12563538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: A 7-month follow-up study.
    Balõtšev R; Haring L; Koido K; Leping V; Kriisa K; Zilmer M; Vasar V; Piir A; Lang A; Vasar E
    Early Interv Psychiatry; 2019 Feb; 13(1):101-109. PubMed ID: 28719155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early insulin resistance predicts weight gain and waist circumference increase in first-episode psychosis--A one year follow-up study.
    Keinänen J; Mantere O; Kieseppä T; Mäntylä T; Torniainen M; Lindgren M; Sundvall J; Suvisaari J
    Schizophr Res; 2015 Dec; 169(1-3):458-463. PubMed ID: 26589392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comment about the article "Psychopharmaceuticals and diabetes" of Ress C, Tschoner A, Kaser S, and Ebenbichler CF in Wiener Medizinische Wochenschrift 2011; 161/21-22: 531-42].
    Ulrich S
    Wien Med Wochenschr; 2012 Dec; 162(23-24):541-2; author reply 543. PubMed ID: 23135252
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.
    Chen CK; Chen YC; Huang YS
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):17-22. PubMed ID: 19067997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication.
    Eapen V; Shiers D; Curtis J
    Aust N Z J Psychiatry; 2013 May; 47(5):435-42. PubMed ID: 23047958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders.
    Scheffler F; Kilian S; Chiliza B; Asmal L; Phahladira L; du Plessis S; Kidd M; Murray RM; Di Forti M; Seedat S; Emsley R
    Schizophr Res; 2018 Sep; 199():90-95. PubMed ID: 29519756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis.
    Basoglu C; Oner O; Gunes C; Semiz UB; Ates AM; Algul A; Ebrinc S; Cetin M; Ozcan O; Ipcioglu O
    Int Clin Psychopharmacol; 2010 May; 25(3):165-71. PubMed ID: 21811193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.